Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation.
Gil-Martínez M, Rodrigo-Muñoz JM, Lorente-Sorolla C, de Castro ZG, Mínguez P, Cañas JA, Valverde-Monge M, Bernaola J, Pinillos-Robles EJ, Betancor D, Fernández-Nieto M, Sastre J, Rodríguez-Nieto MJ, Del Pozo V.
Gil-Martínez M, et al. Among authors: del pozo v.
Allergy. 2024 Sep;79(9):2551-2553. doi: 10.1111/all.16190. Epub 2024 Jun 6.
Allergy. 2024.
PMID: 38841822
No abstract available.